로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > TrkB

TrkB

요약

Name:Neurotrophic tyrosine kinase receptor type 2
Target Synonym:EC:2.7.10.1,Tropomyosin-related kinase B,Trk-B,GP145-TrkB,NTRK2,Neurotrophic Tyrosine Kinase Receptor Type 2,TRKB,BDNF-Tropomyosine Receptor Kinase B,BDNF/NT-3 Growth Factors Receptor,Tyrosine Kinase Receptor B,TrkB Tyrosine Kinase,EC 2.7.10.1,OBHD,Receptor, trkB,Neurotrophic Receptor Tyrosine Kinase 2,Neurotrophic Tyrosine Kinase, Receptor, Type 2,EIEE58,EC 2.7.10
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

NT2-H5254-ELISA
 TrkB ELISA

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 2 μg/mL (100 μL/well) can bind Human TrkB, Fc Tag (Cat. No. NT2-H5254) with a linear range of 1-20 ng/mL (Routinely tested).

NT2-H5228-ELISA
 TrkB ELISA

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 1 μg/mL (100 μL/well) can bind Human TrkB, His Tag (Cat. No. NT2-H5228) with a linear range of 2-78 ng/mL (Routinely tested).

Synonym Name

NTRK2,TRKB,GP145-TrkB

Background

Neurotrophic tyrosine kinase receptor type 2 (NTRK2) is also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is ¡°ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate¡±. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Srl Rozlytrek, 罗圣全 Japan Carcinoma, Non-Small-Cell Lung Chugai Pharmaceutical Co Ltd 2019-06-18 Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Lymphoproliferative Disorders; Colorectal Neoplasms; Sarcoma; Brain Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 United States Solid tumours Bayer Healthcare Pharmaceuticals Inc 2018-11-26 Glioma; Multiple Myeloma; Urinary Bladder Neoplasms; Histiocytosis, Langerhans-Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Lung Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Fibrosarcoma; Rhabdomyosarcoma; Medulloblastoma; Leukemia; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Colonic Neoplasms Details
Repotrectinib BMS-986472; ZL-2308; TPX-0005 Approved Turning Point Therapeutics Inc 奥凯乐, Augtyro United States Carcinoma, Non-Small-Cell Lung Bristol-Myers Squibb Company 2023-11-15 Solid tumours; Neoplasms; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Brain metastases; Carcinoma, Non-Small-Cell Lung Details
Cabozantinib S-malate XL-184; BMS-907351; RO7047650; RO-7047650 Approved Exelixis Inc Cometriq, Cabometyx United States Thyroid Neoplasms; Carcinoma, Neuroendocrine Exelixis Inc 2012-11-29 Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Solid tumours; Skin Melanoma; Bone metastases; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
FCN-011 FCN-011 Phase 2 Clinical Fochon Pharmaceuticals Ltd Solid tumours Details
ACD-856 ACD-856 Phase 1 Clinical Alzecure Pharma Ab Alzheimer Disease; Cognition Disorders Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
FB-1001 FB_-1001; FB-1001; FB1001 Phase 1 Clinical 4b Technologies (Suzhou) Ltd Optic Neuropathy, Ischemic; Optic Nerve Diseases; Glaucoma; Glaucoma, Angle-Closure Details
BrAD-R13 BrAD-R13; BrADR13 Phase 1 Clinical Shanghai Braegen Pharmaceutical Co Ltd Alzheimer Disease Details
PBI-200 PBI-200 Phase 1 Clinical Pyramid Biosciences Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms Details

This web search service is supported by Google Inc.

totop